JP2012510803A5 - - Google Patents

Download PDF

Info

Publication number
JP2012510803A5
JP2012510803A5 JP2011539034A JP2011539034A JP2012510803A5 JP 2012510803 A5 JP2012510803 A5 JP 2012510803A5 JP 2011539034 A JP2011539034 A JP 2011539034A JP 2011539034 A JP2011539034 A JP 2011539034A JP 2012510803 A5 JP2012510803 A5 JP 2012510803A5
Authority
JP
Japan
Prior art keywords
isolated
isolated peptide
nucleic acid
protease
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011539034A
Other languages
English (en)
Japanese (ja)
Other versions
JP5840498B2 (ja
JP2012510803A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/066395 external-priority patent/WO2010063818A2/en
Publication of JP2012510803A publication Critical patent/JP2012510803A/ja
Publication of JP2012510803A5 publication Critical patent/JP2012510803A5/ja
Application granted granted Critical
Publication of JP5840498B2 publication Critical patent/JP5840498B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011539034A 2008-12-05 2009-12-04 プロテアーゼ耐性ポリペプチドを選択するための方法 Active JP5840498B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12013508P 2008-12-05 2008-12-05
US61/120,135 2008-12-05
PCT/EP2009/066395 WO2010063818A2 (en) 2008-12-05 2009-12-04 Methods for selecting protease resistant polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015147120A Division JP2015231380A (ja) 2008-12-05 2015-07-24 プロテアーゼ耐性ポリペプチドを選択するための方法

Publications (3)

Publication Number Publication Date
JP2012510803A JP2012510803A (ja) 2012-05-17
JP2012510803A5 true JP2012510803A5 (https=) 2013-01-31
JP5840498B2 JP5840498B2 (ja) 2016-01-06

Family

ID=42169477

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011539034A Active JP5840498B2 (ja) 2008-12-05 2009-12-04 プロテアーゼ耐性ポリペプチドを選択するための方法
JP2015147120A Pending JP2015231380A (ja) 2008-12-05 2015-07-24 プロテアーゼ耐性ポリペプチドを選択するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015147120A Pending JP2015231380A (ja) 2008-12-05 2015-07-24 プロテアーゼ耐性ポリペプチドを選択するための方法

Country Status (15)

Country Link
US (3) US8685895B2 (https=)
EP (1) EP2364326B1 (https=)
JP (2) JP5840498B2 (https=)
KR (1) KR101740066B1 (https=)
CN (1) CN102307897B (https=)
AU (1) AU2009324037B2 (https=)
BR (1) BRPI0922772B1 (https=)
CA (1) CA2745448C (https=)
EA (1) EA026508B1 (https=)
ES (1) ES2688621T3 (https=)
IL (1) IL212923A0 (https=)
MX (1) MX2011005874A (https=)
SG (1) SG194383A1 (https=)
WO (1) WO2010063818A2 (https=)
ZA (1) ZA201103575B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2364326B1 (en) * 2008-12-05 2018-07-04 Glaxo Group Limited Methods for selecting protease resistant polypeptides
US9012609B2 (en) 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
WO2012022703A2 (en) * 2010-08-20 2012-02-23 Glaxo Group Limited Improved anti-serum albumin binding variants
JP6210982B2 (ja) * 2012-06-22 2017-10-11 オリンパス株式会社 膵液成分含有試料の調製方法、及び膵液成分を含有する生体試料の室温保存用キット
CN105658659A (zh) * 2013-07-15 2016-06-08 北卡罗来纳州大学 蛋白酶抗性肽配体
BR112016004355A2 (pt) 2013-08-30 2017-10-17 Aprilbio Co Ltd constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo
US10294306B2 (en) * 2015-05-28 2019-05-21 Bio-Rad Laboratories, Inc. Affinity ligands and methods relating thereto
TWI726889B (zh) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
JP6766253B2 (ja) * 2017-03-28 2020-10-07 森永乳業株式会社 新規ビフィドバクテリウム属細菌
CN113766930B (zh) * 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
US11584781B2 (en) * 2019-12-30 2023-02-21 Eligo Bioscience Chimeric receptor binding proteins resistant to proteolytic degradation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
EP4204460A4 (en) 2020-08-26 2024-09-25 Twist Bioscience Corporation METHODS AND COMPOSITIONS RELATING TO GLP1R VARIANTS
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
ES2230701T3 (es) 1997-07-07 2005-05-01 Medical Research Council Procedimiento de seleccion in vitro.
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
ES2299244T3 (es) 1998-05-13 2008-05-16 Domantis Limited Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas.
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
AU3040101A (en) 2000-02-03 2001-08-14 Domantis Limited Combinatorial protein domains
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
WO2002095076A2 (en) * 2001-05-23 2002-11-28 Kabushiki Kaisha Toyota Chuo Kenkyusho Modified polypeptides having protease-resistance and/or protease-sensitivity
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
BR122019021416A2 (https=) 2003-09-19 2019-12-21
ATE479760T1 (de) 2004-03-24 2010-09-15 Domantis Ltd Universelles signalpeptid gas1
CN101128487B (zh) * 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
EP2084182B1 (en) * 2006-10-03 2013-08-28 Cadila Healthcare Limited Antidiabetic compounds
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
SG189682A1 (en) * 2008-03-31 2013-05-31 Glaxo Group Ltd Drug fusions and conjugates
EP2364326B1 (en) * 2008-12-05 2018-07-04 Glaxo Group Limited Methods for selecting protease resistant polypeptides
EP2398825B1 (en) * 2009-02-19 2017-10-25 Glaxo Group Limited Single variable domain against serum albumin

Similar Documents

Publication Publication Date Title
JP2012510803A5 (https=)
Lee et al. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1
US20130040877A1 (en) Long-acting y2 receptor agonists
NZ596778A (en) Glucose-regulating polypeptides and methods of making and using same
NZ597685A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
JP2014510518A5 (https=)
JP2013545724A5 (https=)
JP2007513634A5 (https=)
JP2016512213A5 (https=)
EA200901108A1 (ru) Соагонисты глюкагоновых/glp-1-рецепторов
JP2016512213A (ja) 肥満の治療のためのペグ化グルカゴン及びglp−1コアゴニスト
US20210221866A1 (en) Protease-resistant lipidated glp-1 analogs
JP2015504052A5 (https=)
MX2008009493A (es) Peptido novedoso y uso del mismo.
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
WO2023148366A1 (en) Glp-1 and glucagon dual agonist peptides with improved biological stability
KR20190017017A (ko) 프로테아제-내성 모노-지질화된 펩타이드
CY1111630T1 (el) Παραγωγα κυτοκινων
WO2006111946A3 (en) Toll-like receptor 14 (tlr14 ) and use thereof
JP2020511425A5 (https=)
JP2008517998A5 (https=)
WO2007064844A3 (en) Anti-viral griffithsin compounds, compositions, and methods of use
CN120530127A (zh) 新型三重glp-1/gip/胰高血糖素受体激动剂及包括其的用于预防或治疗肥胖症的药物组合物
DK1913020T3 (da) Immunogene konstrukter
WO2008084652A1 (ja) 血管内皮細胞結合性ペプチド